News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,103 Results
Type
Article (39747)
Company Profile (248)
Press Release (660108)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204193)
Career Advice (2008)
Deals (35422)
Drug Delivery (95)
Drug Development (81067)
Employer Resources (172)
FDA (16191)
Job Trends (14865)
News (345252)
Policy (32551)
Tag
Academia (2556)
Accelerated approval (5)
Adcomms (20)
Allergies (87)
Alliances (49445)
ALS (95)
Alzheimer's disease (1384)
Antibody-drug conjugate (ADC) (132)
Approvals (16188)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2321)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (155)
Cell therapy (438)
Cervical cancer (20)
Clinical research (66105)
Collaboration (857)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (251)
Cystic fibrosis (102)
Data (2338)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (276)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (98)
Earnings (87073)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112676)
Executive appointments (743)
FDA (17571)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (773)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (719)
Government (4433)
Grass and pollen (5)
Guidances (162)
Healthcare (18821)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (77)
Medical device (13385)
Medtech (13390)
Mergers & acquisitions (19468)
Metabolic disorders (709)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1943)
NextGen: Class of 2025 (6512)
Non-profit (4481)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57349)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20595)
Phase II (29114)
Phase III (21685)
Pipeline (1385)
Policy (147)
Postmarket research (2563)
Preclinical (8761)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (385)
Real estate (5908)
Recruiting (65)
Regulatory (22334)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (132)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (700)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (115)
Last 7 days (962)
Last 30 days (3214)
Last 365 days (32474)
2025 (11949)
2024 (35223)
2023 (40076)
2022 (51179)
2021 (55712)
2020 (54088)
2019 (46543)
2018 (35021)
2017 (32115)
2016 (31488)
2015 (37557)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27330)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37890)
Australia (6194)
California (6427)
Canada (2069)
China (539)
Colorado (274)
Connecticut (281)
Delaware (158)
Europe (81424)
Florida (957)
Georgia (216)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (922)
Massachusetts (4776)
Michigan (226)
Minnesota (405)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1809)
North Carolina (992)
North Dakota (8)
Northern California (2837)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1430)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2414)
Tennessee (106)
Texas (951)
United States (24068)
Utah (188)
Virginia (152)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (56)
700,103 Results for "3dm inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
April 17, 2024
·
7 min read
Drug Development
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
DiaMedica Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
June 21, 2023
·
6 min read
Press Releases
CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
May 8, 2025
·
4 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Press Releases
Exagen Inc. Prices Public Offering of Common Stock
May 8, 2025
·
3 min read
Press Releases
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
May 7, 2025
·
5 min read
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
Press Releases
Exagen Inc. Announces Proposed Public Offering of Common Stock
May 8, 2025
·
3 min read
Press Releases
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
May 12, 2025
·
5 min read
Press Releases
Axogen, Inc. Reports 2025 First Quarter Financial Results
May 9, 2025
·
14 min read
1 of 70,011
Next
